Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy
Clinical trial NCT02271139 · NO_LONGER_AVAILABLE
Trial details
- NCT number
- NCT02271139
- Sponsor
- Genentech, Inc.
- Status
- NO_LONGER_AVAILABLE
- Study type
- EXPANDED_ACCESS
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.